CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.

Shares of Novo Nordisk climbed 4.5% on Wednesday after the Danish pharmaceutical giant reported a stronger-than-expected ...

Novo is employing a different strategy with cagrisema and now amycretin, which both target GLP-1 and the hormone amylin. Novo reported Phase 1 data for an oral form of amycretin about a year ago. The ...

The offerings reflect an increase in IPO activity that could continue, as four other biotechs recently outlined plans to go ...

Danish pharmaceutical behemoth Novo Nordisk reported better-than-expected net profit in the fourth quarter, amid soaring ...

Aconcagua Bio Inc. has divulged calcitonin receptor (CALCR; CT-R) and amylin receptor agonists reported to be useful for the treatment of pain, neurodegeneration, metabolic diseases, bone and ...

Amylin is a hormone that helps regulate blood sugar in the body. "Recently showcased at ADA (American Diabetes Association), the program demonstrated promising preclinical weight-loss signals ...

Like those injections, the new drug targets gut hormone GLP-1 but additionally mimics amylin, a hormone released by the pancreas that suppresses hunger. Novo’s U.S.-listed shares jumped over 10% ...